{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:9949"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:9949","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Immune responses to human cytomegalovirus (HCMV) reactivation in allogeneic haematopoietic stem cell transplantation (HSCT)","abstract":"Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is commonly used to treat a range of haematological malignancies with Human cytomegalovirus (HCMV) reactivation as one of the major risk factors. HCMV reactivation is crucial as it can lead to HCMV disease and increase mortality. The CMV serostatus of the recipient and donor in the HSCT setting plays a role in determining the risk of the patient getting viral reactivation. Recent studies have also suggested that CMV reactivation after HSCT is associated with faster immune reconstitution and reduction of leukaemia relapse. This project studied the phenotype kinetics of immune cells including Natural Killer (NK) cells, CD4\\(^+\\), CD8\\(^+\\) and TCR\\(\\gamma\\delta\\) T cells in HSCT patients after CMV reactivation. Also, the tetramer technique was used to study CMV specific CD8\\(^+\\) and CD4\\(^+\\) T cells responses reconstitution in these HSCT patients. Our data show that CMV reactivation gives significant impact on immune reconstitution of allo-HSCT by imprinting the immune cells with phenotypes specific to CMV. One major impact on NK cells seen in allo-HSCT with CMV reactivation is the huge expansion of CD56\\(^{dim}\\)CD16\\(^{bright}\\) NKG2C\\(^+\\) NK cells or the controversial ‘memory-like’ NK cells. The expansion of this NK population results in enhanced cytokines production after stimulation. In overall, the study of CMV reactivation in HSCT will ultimately give some insight of how to modify the clinical practice to target CMV reactivation and improve the overall clinical outcome.","abstract_html":"Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is commonly used to treat a range of haematological malignancies with Human cytomegalovirus (HCMV) reactivation as one of the major risk factors. HCMV reactivation is crucial as it can lead to HCMV disease and increase mortality. The CMV serostatus of the recipient and donor in the HSCT setting plays a role in determining the risk of the patient getting viral reactivation. Recent studies have also suggested that CMV reactivation after HSCT is associated with faster immune reconstitution and reduction of leukaemia relapse. This project studied the phenotype kinetics of immune cells including Natural Killer (NK) cells, CD4<span class=\"etd-inline-math\"><sup>+</sup></span>, CD8<span class=\"etd-inline-math\"><sup>+</sup></span> and TCR<span class=\"etd-inline-math\">&gamma;&delta;</span> T cells in HSCT patients after CMV reactivation. Also, the tetramer technique was used to study CMV specific CD8<span class=\"etd-inline-math\"><sup>+</sup></span> and CD4<span class=\"etd-inline-math\"><sup>+</sup></span> T cells responses reconstitution in these HSCT patients. Our data show that CMV reactivation gives significant impact on immune reconstitution of allo-HSCT by imprinting the immune cells with phenotypes specific to CMV. One major impact on NK cells seen in allo-HSCT with CMV reactivation is the huge expansion of CD56<span class=\"etd-inline-math\"><sup>dim</sup></span>CD16<span class=\"etd-inline-math\"><sup>bright</sup></span> NKG2C<span class=\"etd-inline-math\"><sup>+</sup></span> NK cells or the controversial ‘memory-like’ NK cells. The expansion of this NK population results in enhanced cytokines production after stimulation. In overall, the study of CMV reactivation in HSCT will ultimately give some insight of how to modify the clinical practice to target CMV reactivation and improve the overall clinical outcome.","abstract_has_math":true,"creators":["Hassan, Norfarazieda"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-07","date_published":"2020-07","updated_at":"2026-11-19T09:30:56Z","subjects":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/9949/7/Hassan2020PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A9949","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["other"]},{"key":"dc:creator","label":"Author","values":["Hassan, Norfarazieda"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2020-07-20"]},{"key":"dc:date.issued","label":"Date","values":["2020-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cancer and Genomic Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/9949/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/9949/7/Hassan2020PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is commonly used to treat a range of haematological malignancies with Human cytomegalovirus (HCMV) reactivation as one of the major risk factors. HCMV reactivation is crucial as it can lead to HCMV disease and increase mortality. The CMV serostatus of the recipient and donor in the HSCT setting plays a role in determining the risk of the patient getting viral reactivation. Recent studies have also suggested that CMV reactivation after HSCT is associated with faster immune reconstitution and reduction of leukaemia relapse. This project studied the phenotype kinetics of immune cells including Natural Killer (NK) cells, CD4\\(^+\\), CD8\\(^+\\) and TCR\\(\\gamma\\delta\\) T cells in HSCT patients after CMV reactivation. Also, the tetramer technique was used to study CMV specific CD8\\(^+\\) and CD4\\(^+\\) T cells responses reconstitution in these HSCT patients. Our data show that CMV reactivation gives significant impact on immune reconstitution of allo-HSCT by imprinting the immune cells with phenotypes specific to CMV. One major impact on NK cells seen in allo-HSCT with CMV reactivation is the huge expansion of CD56\\(^{dim}\\)CD16\\(^{bright}\\) NKG2C\\(^+\\) NK cells or the controversial ‘memory-like’ NK cells. The expansion of this NK population results in enhanced cytokines production after stimulation. In overall, the study of CMV reactivation in HSCT will ultimately give some insight of how to modify the clinical practice to target CMV reactivation and improve the overall clinical outcome."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Immune responses to human cytomegalovirus (HCMV) reactivation in allogeneic haematopoietic stem cell transplantation (HSCT)"]}]}],"canonical_facts":{"dc:contributor.sponsor":["other"],"dc:creator":["Hassan, Norfarazieda"],"dc:date":["2020-07-20"],"dc:date.issued":["2020-07"],"dc:description.abstract":["Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is commonly used to treat a range of haematological malignancies with Human cytomegalovirus (HCMV) reactivation as one of the major risk factors. HCMV reactivation is crucial as it can lead to HCMV disease and increase mortality. The CMV serostatus of the recipient and donor in the HSCT setting plays a role in determining the risk of the patient getting viral reactivation. Recent studies have also suggested that CMV reactivation after HSCT is associated with faster immune reconstitution and reduction of leukaemia relapse. This project studied the phenotype kinetics of immune cells including Natural Killer (NK) cells, CD4\\(^+\\), CD8\\(^+\\) and TCR\\(\\gamma\\delta\\) T cells in HSCT patients after CMV reactivation. Also, the tetramer technique was used to study CMV specific CD8\\(^+\\) and CD4\\(^+\\) T cells responses reconstitution in these HSCT patients. Our data show that CMV reactivation gives significant impact on immune reconstitution of allo-HSCT by imprinting the immune cells with phenotypes specific to CMV. One major impact on NK cells seen in allo-HSCT with CMV reactivation is the huge expansion of CD56\\(^{dim}\\)CD16\\(^{bright}\\) NKG2C\\(^+\\) NK cells or the controversial ‘memory-like’ NK cells. The expansion of this NK population results in enhanced cytokines production after stimulation. In overall, the study of CMV reactivation in HSCT will ultimately give some insight of how to modify the clinical practice to target CMV reactivation and improve the overall clinical outcome."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/9949/7/Hassan2020PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cancer and Genomic Sciences"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/9949/"],"dc:subject":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public"],"dc:title":["Immune responses to human cytomegalovirus (HCMV) reactivation in allogeneic haematopoietic stem cell transplantation (HSCT)"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:30:56Z"}